Get started
Author

Anu Räsänen

Observed names: Anu Räsänen, Räsänen, Anu
Observed institution: Kymenlaakson keskussairaala
OpenAlex ID: A5110163836
Combination of pegylated IFN-α2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia
2011 · Bengt Simonsson, Tobias Gedde-Dahl, et al. · Blood · 194
PDF
Prolonged immunochemotherapy with rituximab, cytarabine and fludarabine added to cyclophosphamide, doxorubicin, vincristine and prednisolone and followed by rituximab maintenance in untreated elderly patients with mantle cell lymphoma: a prospective study by the Finnish Lymphoma Group
2012 · Riikka Räty, Tuomo Honkanen, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 18
RVD induction and autologous stem cell transplantation followed by lenalidomide maintenance in newly diagnosed multiple myeloma: a phase 2 study of the Finnish Myeloma Group
2019 · Sini Luoma, Pekka Anttila, et al. · Annals of Hematology · 16
PDF
Imatinib and pegylated IFN ‐α2b discontinuation in first‐line chronic myeloid leukemia patients following a major molecular response
2013 · Perttu Koskenvesa, Anna Kreutzman, et al. · European Journal Of Haematology · 11
Imatinib Discontinuation Following a Major Molecular Response: Impact of Interferon Alpha and Leukemia Stem Cell Burden (The STOP Study).
2008 · Perttu Koskenvesa, Satu Mustjoki, et al. · Blood · 5
RVD + ASCT + Lenalidomide Maintenance Benefits Patients without High-Risk Cytogenetics and Results in Recovery of the Normal Plasma Cell Composition in Bone Marrow
2016 · Raija Silvennoinen, Pekka Anttila, et al. · Blood · 4
A Randomized Phase II Study Comparing Imatinib and the Combination of Imatinib and Pegylated Interferon Alpha-2b in Newly Diagnosed Non-High Risk Chronic Myeloid Leukemia (CML) Patients in Complete Hematological Remission After Imatinib Induction Therapy.
2009 · Bengt Simonsson, Tobias Gedde-Dahl, et al. · Blood · 3
A Phase 2 Study of Carfilzomib Plus Elotuzumab Plus Dexamethasone for Myeloma Patients Relapsed after 1-3 Prior Treatment Lines
2018 · Raija Helena Silvennoinen, Dimitrios Tsallos, et al. · Blood · 2
A Prospective Phase 2 Study to Assess Immunophenotypic Remission after Lenalidomide-Based Induction Followed By ASCT and Lenalidomide Maintenance in Patients with Newly Diagnosed Multiple Myeloma
2015 · Raija Silvennoinen, Pekka Anttila, et al. · Blood · 1
Timing of patient-reported outcomes assessment of transient symptomatic toxicities from myeloma treatment seems to matter – findings from an Nordic Myeloma Study Group phase II relapse trial.
2019 · Eshøj, Henrik, Nielsen, Lene Kongsgaard ; id_orcid 0000-0003-2083-3870, et al.
Rituximab Maintenance Bimonthly for Two Years after Prolonged Immunochemotherapy in Elderly Patients with Mantle Cell Lymphoma (MCL) Results in Long Remissions: Update with Six-Year Follow-up of a Prospective Study By the Finnish Lymphoma Group
2014 · Riikka Räty, Tuomo Honkanen, et al. · Blood
A Randomized Comparison of Low-Dose Cyclophosphamide + G-CSF Versus G-CSF Alone Mobilization after Lenalidomide-Bortezomib-Dexamethasone (RVD) Induction in Multiple Myeloma
2014 · Raija Silvennoinen, Tuija Lundan, et al. · Blood
Elderly Patients with Mantle Cell Lymphoma (MCL) – Efficacy and Feasibility of Prolonged Immunochemotherapy with Rituximab, Cytarabine and Fludarabine Added to CHOP and Followed by Rituximab Maintenance Treatment. A Prospective Study by the Finnish Lymphoma Group
2008 · Erkki Elonen, Riikka Räty, et al. · Blood
Works count: 13
Citation count: 254
H-index: 5
I10-index: 4
Year
Topic
Type